Amrita Narang, MD
Pediatric Transplant Hepatology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Narang’s office at (650) 497-8000 to ask if they take your plan before you enroll.
California Medical Board record
Licence A132976 · Current
Licensed to practise in California · since 2014 · expires 2028-03-31 · New York Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Pediatrics - Pediatric Gastroenterology
- American Board of Pediatrics - Pediatric Transplant Hepatology
Medicaid work
$36,553 in 2024
Medicaid paid $36,553 for 249 billed services this clinician did in 2024, up to 27 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 182 | $30,785 |
| Prolonged outpatient evaluation and management service(s) time with or without direct patient contact beyond the required time of the primary service when the primary service level has been selected using total time, each 15 minutes of total time (List separately in addition to the code of the outpatient Evaluation and Management service) | 67 | $5,768 |
| 2024 | 249 | 2 | 27 | $36,553 |
| 2023 | 214 | 3 | 27 | $25,163 |
| 2022 | 140 | 3 | 19 | $15,921 |
| 2021 | 174 | 2 | 23 | $21,912 |
| 2020 | 59 | 1 | 15 | $7,342 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 176 | $22,069 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 24 | $2,347 |
| Prolonged outpatient evaluation and management service(s) time with or without direct patient contact beyond the required time of the primary service when the primary service level has been selected using total time, each 15 minutes of total time (List separately in addition to the code of the outpatient Evaluation and Management service) | 14 | $747 |
2022
| Long return visit (40+ min) | 86 | $11,063 |
| PROLNG SVC I/P/OBS 1ST HOUR | 39 | $2,601 |
| OFFICE/OP CONSLTJ NEW/EST PT HIGH MDM 55 MINUTES | 15 | $2,257 |
2021
| Long return visit (40+ min) | 145 | $19,574 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 29 | $2,338 |
2020
| Long return visit (40+ min) | 59 | $7,342 |
Money from drug and device companies
$17,799 in 2025
| 2025 | 2 | 18 | $15,171 | $17,799 |
| 2024 | 2 | 9 | $7,301 | $9,750 |
| 2023 | 3 | 10 | $17,353 | $18,983 |
| 2019 | 1 | 1 | None | $7 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Mirum Pharmaceuticals | Livmarli | $11,767 | 14 payments
|
| Ipsen Biopharmaceuticals | Bylvay | $6,032 | 4 payments
|
See all 18 published payments
| Mirum Pharmaceuticals | Meals · 2025-08-14 | Livmarli | $37 |
| Mirum Pharmaceuticals | Meals · 2025-04-05 | Livmarli | $25 |
| Mirum Pharmaceuticals | Meals · 2025-04-05 | Livmarli | $46 |
| Mirum Pharmaceuticals | Travel · 2025-04-04 | Livmarli | $94 |
| Mirum Pharmaceuticals | Meals · 2025-04-04 | Livmarli | $149 |
| Mirum Pharmaceuticals | Meals · 2025-04-04 | Livmarli | $50 |
| Mirum Pharmaceuticals | Consulting · 2025-04-04 | Livmarli | $4,875 |
| Mirum Pharmaceuticals | Consulting · 2025-04-04 | Livmarli | $5,200 |
| Mirum Pharmaceuticals | Travel · 2025-04-04 | Livmarli | $88 |
| Mirum Pharmaceuticals | Meals · 2025-04-04 | Livmarli | $22 |
| Mirum Pharmaceuticals | Travel · 2025-04-04 | Livmarli | $87 |
| Mirum Pharmaceuticals | Meals · 2025-04-04 | Livmarli | $12 |
| Mirum Pharmaceuticals | Travel · 2025-04-04 | Livmarli | $512 |
| Mirum Pharmaceuticals | Travel · 2025-04-04 | Livmarli | $571 |
| Ipsen Biopharmaceuticals | Paid to speak or teach · 2025-01-21 | Bylvay | $5,096 |
| Ipsen Biopharmaceuticals | Travel · 2025-01-21 | Bylvay | $188 |
| Ipsen Biopharmaceuticals | Travel · 2025-01-21 | Bylvay | $646 |
| Ipsen Biopharmaceuticals | Meals · 2025-01-21 | Bylvay | $102 |
See earlier years (2024, 2023, 2019)
2024: $9,750
| Ipsen Biopharmaceuticals | Bylvay | $6,573 | 3 payments
|
| Mirum Pharmaceuticals | Livmarli | $3,176 | 6 payments
|
2023: $18,983
| Ipsen Biopharmaceuticals | Bylvay | $15,206 | 6 payments
|
| Mirum Pharmaceuticals | Livmarli | $2,341 | 3 payments
|
| Albireo Pharma | Bylvay | $1,436 | 1 payment
|
2019: $7
| Retrophin | (820) Cholbam | $7 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| ALBIREO PHARMA, INC. · A Double-Blind, Randomized, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia Who Have Undergone A Kasai Hepatoportoenterostomy · 2024 | Their institution | $85,727 |
| ALBIREO PHARMA, INC. · A Double-Blind, Randomized, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia Who Have Undergone A Kasai Hepatoportoenterostomy · 2022 | Their institution | $79,003 |
| ALBIREO PHARMA, INC. · A Double-Blind, Randomized, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia Who Have Undergone A Kasai Hepatoportoenterostomy · 2023 | Their institution | $74,936 |
| ALBIREO PHARMA, INC. · A Double-Blind, Randomized, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia Who Have Undergone A Kasai Hepatoportoenterostomy · 2025 | Their institution | $69,183 |
| ALBIREO PHARMA, INC. · An Open-Label Extension Study To Evaluate Long-Term Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia (Bold-Ext) · 2024 | Their institution | $31,154 |
| ALBIREO PHARMA, INC. · An Open-Label Extension Study To Evaluate Long-Term Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia (Bold-Ext) · 2025 | Their institution | $27,993 |
| ALBIREO PHARMA, INC. · An Open-Label Extension Study To Evaluate Long-Term Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia (Bold-Ext) · 2023 | Their institution | $27,279 |
| Mirum Pharmaceuticals, Inc. · Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai (Embark) · 2023 | Their institution | $22,427 |
Professional record
- NPI
- 1679831010
- Licence
- CA A132976California A132976: Current · expires 2028-03-31
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2080T0004X (2080T0004X); Pediatrics (208000000X); Federal specialty code 2080P0206X (2080P0206X)
- Mailing address
- 725 Welch Rd, Palo Alto, CA, 94304
- NPI first listed
- 2012-04-23
- NPI last updated
- 2024-04-10
- NPI record certified
- 2024-04-10
This is when the NPI record was last certified, not a medical board exam.